Peer-reviewed independent bench testing examines the TransForm™ mitral valve repair ring and highlights lifetime management considerations in cardiac surgery. Our findings demonstrate that the TransForm™ ring does indeed circularize and can anchor a balloon-expandable THV to facilitate TMViR.” — (Allen et. al, 2026) DENVER, CO, UNITED STATES, February 13, 2026 / EINPresswire.com / -- Genesee BioMedical, Inc. acknowledges the recent publication of a new peer-reviewed, open-access article in Struc

Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it. On Thursday, Lilly filed a notice to appeal a September district court decision that said the FDA didn’t violate the law when it decided to classify retatrutide as a drug instead of a biologic. Lilly is bringing the case to the US Court of Appeals for the Seventh Circuit. How a product is classified determines what marketing

Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash and marketable securities, including net proceeds from recent PIPE transaction, expected to provide runway into calendar 2027 Signed binding letter of intent for XTL Biopharmaceuticals to acquire 85% of Beyond Air's subsidiary NeuroNOS; Beyond Air to receive up to $32.5 million from the combina

GALWAY, Ireland, Feb. 13, 2026 /PRNewswire/ -- InVera Medical, an Irish medical technology company, has received European regulatory approval for a new minimally invasive device designed to help physicians deliver treatment more effectively to diseased leg veins, including varicose veins. The approval, known as a CE Mark, allows the company's InVera Infusion Device to be marketed and used across the European Union. Unlike many existing technologies that burn the vein, the InVera device uses a n

TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company focused on AI-driven clinical trial optimization and precision patient stratification, today announced that it will be uplisting to the Toronto Stock Exchange (the “TSX“). The common shares of the Company (the “Common Shares“) will be voluntarily delisted from the Canadian Securities Exchange (the “CSE“) effective as of close of market on Febr

The Centers for Medicare & Medicaid Services (CMS) Innovation Center announced that numerous major health plans from across the nation have signed on to participate in the ACCESS pledge. ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) is a model that expands access to technology-supported care for individuals on Original Medicare with obesity, diabetes, musculoskeletal pain and depression. Plan participants who signed on include Blue Shield of California, BlueCross BlueShield

Moderna’s finance chief said it’s “too early to tell” whether the company’s goal of reaching break-even cash flow will be pushed back — once again — after the FDA declined to review its flu shot for adults 50 and older. The comments from Jamey Mock on Moderna’s earnings call Friday underscore the financial implications of the FDA’s refusal-to-file letter announced earlier this week . The agency argued that Moderna sped past recommendations to use a higher-dose flu shot as the comparator product

Lundbeck said its next-generation migraine prevention drug cleared the bar in a Phase 2b study, setting the company up for late-stage trials that could start this year. The Danish drugmaker said the IV-delivered medicine, bocunebart (Lu AG09222), was better than placebo at reducing the number of monthly migraine days that patients experienced during a 12-week review. The results were statistically significant. To be included in the trial, dubbed PROCEED , patients had to have failed one to four

Eli Lilly is continuing to stockpile its obesity pill orforglipron months ahead of its expected US launch. In a Thursday SEC filing , the drugmaker said it has $1.5 billion in “pre-launch inventories” as of Dec. 31, “primarily related” to orforglipron. Last February, Lilly said it had already stockpiled $548 million worth of the oral GLP-1 candidate, ready to be distributed as soon as the drug gains regulatory approval. Orforglipron is expected to be approved by the FDA in April. The Indianapoli

While biotechs were deterred from listing on the public markets last year due to a cold reception by investors, Agomab Therapeutics\' CEO \"sees the climate and the reception changing.\"\n Whisper it, but we may finally be seeing the IPO window reopening in 2026.Biotech listings saw their heyday in the middle of the COVID-19 pandemic, when an incredible 87 U.S.-based drug developers surfed a wave of goodwill from generalist investors onto the public markets in 2021. That interest subsided